Personalized treatment approach for rectal adenocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on patients with rectal adenocarcinoma, stratifying them into three groups based on their clinical stage. It investigates a multimodal therapeutic approach that emphasizes organ preservation and minimally invasive techniques, such as laparoscopic and robotic surgery, to reduce the impact on patients' quality of life. The study also explores experimental chemoradiotherapy for patients who refuse surgery, aiming to minimize local relapse risk while maintaining a rigorous surveillance protocol. The goal is to provide tailored treatment options that align with the specific needs of each patient group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged ≥18 yrs old
* Patients able to sign the informed consent
* Patients with High Risk pT1 rectal adenocarcinoma endoscopically excised
* Patients with cT2-3aN0 rectal adenocarcinoma who has complete/major response to EXPERIMENTAL CRT
* Patients with cT3b4N0-1 rectal adenocarcinoma who has complete/major response to STANDARD CRT

Exclusion Criteria:

* cT2-4 any NM0 who don't reach cCR or cMR after experimental/standard CRT
* Pregnancy

Where it's running

• Department of Surgical Oncology - FPO-IRCCS Institute for Cancer Research and Treatment
  Candiolo, Turin, Italy Recruiting

Study contacts

• Principal investigator: Felice Borghi, MD — Fondazione del Piemonte per l'Oncologia
• Study coordinator: Alfredo Mellano, MD
• Email: alfredo.mellano@ircc.it
• Phone: +390119933445

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant Radiotherapy Before Surgery for Locally Advanced Proximal Rectal Cancer

  This study tests whether giving radiotherapy before surgery reduces cancer return in people with locally advanced proximal rectal cancer.

  Recruiting Istanbul University · Istanbul · NCT07802197

• Short-course radiotherapy followed by PD-1 inhibitor and FOLFOX vs standard chemoradiotherapy for high‑risk locally advanced lower rectal cancer

  This trial tests whether giving a short course of radiotherapy followed by a PD-1 inhibitor and FOLFOX can be better than the usual long-course chemoradiotherapy for adults with high‑risk, locally advanced, pMMR/MSS lower rectal cancer.

  Recruiting Phase 2 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou · NCT07669220

• Short-course radiotherapy plus intensified chemotherapy and targeted therapy with immunotherapy for high-risk rectal cancer

  This trial tests whether adding targeted therapy and a PD-1 inhibitor to a short course of radiotherapy and standard chemotherapy helps high-risk pMMR/MSS rectal cancer patients, compared with the same radiotherapy and chemotherapy alone.

  Recruiting Phase 3 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07549399

• First-line trastuzumab-deruxtecan with capecitabine and bevacizumab for HER2-positive metastatic colorectal cancer

  This trial tests whether giving trastuzumab-deruxtecan together with capecitabine and bevacizumab as first treatment helps people with HER2-positive metastatic or unresectable colorectal cancer shrink tumors and respond better.

  Recruiting at 28 sites Phase 2 Gruppo Oncologico del Nord-Ovest · Lyon and 27 other locations · NCT07407465

• Long-term follow-up of bowel function (LARS) after rectal cancer surgery and neoadjuvant therapy

  This project will see how bowel symptoms (LARS) change over time after sphincter-preserving rectal cancer surgery and whether different neoadjuvant treatment schedules affect those symptoms.

  Recruiting University Hospital, Antwerp · Edegem, Antwerp · NCT07339904

• Rectal brachytherapy boost to try to avoid surgery for low-lying residual rectal cancer after total neoadjuvant therapy

  This trial will try focal internal radiation (rectal brachytherapy) for people with low-lying residual rectal adenocarcinoma after total neoadjuvant therapy to see if it can produce complete responses and avoid surgery.

  Recruiting Phase 2 University of Colorado, Denver · Aurora, Colorado and 2 other locations · NCT07292298

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.